Loading…
Reported covered position: Chief of Staff, Rep. Rosa DeLauro (D-CT); Director, Rep. Sherrod Brown (D-OH); Legislative Assistant, Rep. Tom Foglietta (D-PA)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
DeOndra Dixon INCLUDE Project Act of 2025
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
DeOndra Dixon INCLUDE Project Act of 2025
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY via BLUEBIRD STRATEGIES
2026 · third_quarter · Q3
Funding eligibility for FSHD research as part of the FY26 Senate Defense Peer Reviewed Medical Research Program
Filing targets: SENATE
CELLTRION USA, INC. via BLUEBIRD STRATEGIES
2026 · third_quarter · Q3
Source: Senate LDA
| NCATS ALLIANCE |
| 13 |
| 2024–2026 |
| CELLTRION USA, INC. | 8 | 2024–2026 |
| FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY | 8 | 2025–2026 |
| BOEHRINGER INGELHEIM USA CORPORATION | 5 | 2023–2024 |
| CLICK THERAPEUTICS, INC. | 5 | 2023–2024 |
| LUMINOPIA, INC. | 5 | 2023–2024 |
| ATA ACTION | 4 | 2025 |
| FAEGRE BAKER DANIELS CONSULTING (ON BEHALF OF GLOBAL DOWN SYNDROME FOUNDATION) | 4 | 2019–2020 |
| MINDMAZE INC. | 4 | 2023 |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | 4 | 2023 |
| DIGITAL THERAPEUTICS ALLIANCE | 3 | 2024–2025 |
DeOndra Dixon INCLUDE Project Act of 2025
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.
Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.
DeOndra Dixon INCLUDE Project Act of 2026
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
DeOndra Dixon INCLUDE Project Act of 2026
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
DeOndra Dixon INCLUDE Project Act of 2026
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) Coverage/reimbursement DTx products FDA Prescription Drug Use-Related Software (PDURS)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) Coverage/reimbursement DTx products FDA Prescription Drug Use-Related Software (PDURS)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
DeOndra Dixon INCLUDE Project Act of 2025
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
DeOndra Dixon INCLUDE Project Act of 2025
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
DeOndra Dixon INCLUDE Project Act of 2025
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) Coverage/reimbursement DTx products FDA Prescription Drug Use-Related Software (PDURS)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Access to Prescription Digital Therapeutics Act of 2025
Client: ATA ACTION · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) Coverage/reimbursement DTx products FDA Prescription Drug Use-Related Software (PDURS)
DeOndra Dixon INCLUDE Project Act of 2026
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
DeOndra Dixon INCLUDE Project Act of 2026
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
DeOndra Dixon INCLUDE Project Act of 2026
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458/S. 723) American Medical Innovation and Investment Act (H.R. 8816)
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
DeOndra Dixon INCLUDE Project Act of 2024
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (HR 7406/S.3981)
DeOndra Dixon INCLUDE Project Act of 2024
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (HR 7406/S.3981)
American Medical Innovation and Investment Act of 2024
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458/S. 723) American Medical Innovation and Investment Act (H.R. 8816)
American Medical Innovation and Investment Act of 2024
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
American Medical Innovation and Investment Act of 2024
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Peggy Lillis Clostridioides difficile Inclusion Act
Client: THE PEGGY LILLIS FOUNDATION · Firm: BLUEBIRD STRATEGIES
Peggy Lillis C. difficile Inclusion Act (H.R. 9098) CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act.
Peggy Lillis Clostridioides difficile Inclusion Act
Client: THE PEGGY LILLIS FOUNDATION · Firm: BLUEBIRD STRATEGIES
Peggy Lillis C. difficile Inclusion Act (H.R. 9098) CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act.
DeOndra Dixon INCLUDE Project Act of 2024
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (HR 7406/S.3981)
DeOndra Dixon INCLUDE Project Act of 2024
Client: GLOBAL DOWN SYNDROME FOUNDATION · Firm: BLUEBIRD STRATEGIES
DeOndra Dixon INCLUDE Project Act (HR 7406/S.3981)
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: DIGITAL THERAPEUTICS ALLIANCE · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458/S. 723) American Medical Innovation and Investment Act (H.R. 8816)
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: MINDMAZE INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: MINDMAZE INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: MINDMAZE INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: MINDMAZE INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: MINDMAZE INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: MINDMAZE INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: MINDMAZE INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: MINDMAZE INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: CLICK THERAPEUTICS, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: LUMINOPIA, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Access to Prescription Digital Therapeutics Act of 2023
Client: OTSUKA AMERICA PHARMACEUTICAL, INC. · Firm: BLUEBIRD STRATEGIES
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Public health data and surveillance of C. diff; antibiotic stewardship; H.R. 3932 / S. 2076, The PASTEUR Act.
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Public health data and surveillance of C. diff; antibiotic stewardship; H.R. 3932 / S. 2076, The PASTEUR Act.
Public health data and surveillance of C. diff; antibiotic stewardship; H.R. 3932 / S. 2076, The PASTEUR Act.
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Public health data and surveillance of C. diff; antibiotic stewardship; H.R. 3932 / S. 2076, The PASTEUR Act.
Public health data and surveillance of C. diff; antibiotic stewardship; H.R. 3932 / S. 2076, The PASTEUR Act.
Allergy Testing Access Act of 2021
Client: THERMO FISHER SCIENTIFIC INC · Firm: BLUEBIRD STRATEGIES
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Allergy Testing Access Act of 2021
Client: THERMO FISHER SCIENTIFIC INC · Firm: BLUEBIRD STRATEGIES
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Allergy Testing Access Act of 2021
Client: THERMO FISHER SCIENTIFIC INC · Firm: BLUEBIRD STRATEGIES
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021. Medicare coverage for small cell lung cancer genetic test.
Allergy Testing Access Act of 2021
Client: THERMO FISHER SCIENTIFIC INC · Firm: BLUEBIRD STRATEGIES
H.R. 4114 / S. 701, Allergy Testing Access Act of 2021; asthma policies and diagnostic allergy test coverage; coverage and reimbursement for precision medicine diagnostics.
Public health data and surveillance of C. diff; antibiotic stewardship; H.R. 3932 / S. 2076, The PASTEUR Act.
H.R. 3932 / S. 2076, The PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship.
Issues related to CMS drug pricing, FDA drug regulations, biosimilar coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2026 · third_quarter · Q3
FY27 NIH/NCATS Appropriations Funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2026 · third_quarter · Q3
Advocacy for FY27 HHS Funding; report language on BARDA and C diff drug development
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2026 · third_quarter · Q3
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
NIH INCLUDE Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2026 · third_quarter · Q3
Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2026 · third_quarter · Q3
Funding for myotonic dystrophy research as part of the FY27 Congressionally Directed Medical Research Program & Peer Review Medical Research Program.
Myotonic dystrophy biomedical research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2026 · second_quarter · Q2
FY27 NIH/NCATS Appropriations Funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2026 · second_quarter · Q2
Advocacy for FY27 HHS Funding; report language on BARDA and C diff drug development
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
CELLTRION USA, INC. via BLUEBIRD STRATEGIES
2026 · second_quarter · Q2
Issues related to CMS drug pricing, FDA drug regulations, biosimilar coverage and reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2026 · second_quarter · Q2
Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2026 · second_quarter · Q2
NIH INCLUDE Down syndrome research funding
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY via BLUEBIRD STRATEGIES
2026 · second_quarter · Q2
Funding eligibility for FSHD research as part of the FY26 Senate Defense Peer Reviewed Medical Research Program
Filing targets: SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2026 · second_quarter · Q2
Myotonic dystrophy biomedical research funding
Funding for myotonic dystrophy research as part of the FY27 Congressionally Directed Medical Research Program & Peer Review Medical Research Program.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2026 · first_quarter · 1A
Engage Senate and House on proposed legislation to promote the appropriate use of FDA cleared preeclampsia biomarker testing as part of the Medicaid program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY via BLUEBIRD STRATEGIES
2026 · first_quarter · Q1
Funding eligibility for FSHD research as part of the FY26 Senate Defense Peer Reviewed Medical Research Program
Filing targets: SENATE
CELLTRION USA, INC. via BLUEBIRD STRATEGIES
2026 · first_quarter · Q1
Issues related to drug pricing, FDA drug regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2026 · first_quarter · Q1
FY27 NIH/NCATS Appropriations Funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2026 · first_quarter · Q1
Advocacy for FY27 HHS Funding
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2026 · first_quarter · Q1
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
NIH INCLUDE Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2026 · first_quarter · Q1
Engage Senate and House on proposed legislation to promote the appropriate use of FDA cleared preeclampsia biomarker testing as part of the Medicaid program
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2026 · first_quarter · Q1
Funding for myotonic dystrophy research as part of the FY27 Congressionally Directed Medical Research Program & Peer Review Medical Research Program.
Myotonic dystrophy biomedical research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2025 · third_quarter · Q3
FY26 Appropriations advocacy on behalf of NCATS
FY26 Appropriations advocacy on behalf of NCATS
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2025 · fourth_quarter · Q4
FY26 NIH/NCATS Appropriations Funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2025 · fourth_quarter · Q4
Advocacy for FY26 HHS Funding
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
ATA ACTION via BLUEBIRD STRATEGIES
2025 · fourth_quarter · 4@
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2025 · fourth_quarter · Q4
Engage Senate and House on proposed legislation to promote the appropriate use of FDA cleared preeclampsia biomarker testing as part of the Medicaid program
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CELLTRION USA, INC. via BLUEBIRD STRATEGIES
2025 · fourth_quarter · Q4
Issues related to drug pricing, FDA drug regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2025 · fourth_quarter · Q4
Funding for myotonic dystrophy research as part of the FY26 Congressionally Directed Medical Research Program
Myotonic dystrophy biomedical research funding
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY via BLUEBIRD STRATEGIES
2025 · fourth_quarter · Q4
Funding eligibility for FSHD research as part of the FY26 Senate Defense Peer Reviewed Medical Research Program
Filing targets: SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2025 · fourth_quarter · Q4
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
NIH INCLUDE Down syndrome research funding
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
ATA ACTION via BLUEBIRD STRATEGIES
2025 · fourth_quarter · 4T
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2025 · third_quarter · Q3
Advocacy for FY26 HHS Funding
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
ATA ACTION via BLUEBIRD STRATEGIES
2025 · third_quarter · Q3
Access to Prescription Digital Therapeutics Act of 2025 (H.R.3288/S. 1702)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELLTRION USA, INC. via BLUEBIRD STRATEGIES
2025 · third_quarter · Q3
Issues related to drug pricing, FDA drug regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2025 · third_quarter · Q3
Engage Senate and House on proposed legislation to promote the appropriate use of FDA cleared preeclampsia biomarker testing as part of the Medicaid program
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2025 · third_quarter · Q3
NIH INCLUDE Down syndrome research funding
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY via BLUEBIRD STRATEGIES
2025 · third_quarter · Q3
Funding eligibility for FSHD research as part of the FY26 Senate Defense Peer Reviewed Medical Research Program
Filing targets: SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2025 · third_quarter · Q3
Funding for myotonic dystrophy research as part of the FY26 Congressionally Directed Medical Research Program
Myotonic dystrophy biomedical research funding
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
ATA ACTION via BLUEBIRD STRATEGIES
2025 · third_quarter · RR
Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) Coverage/reimbursement DTx products FDA Prescription Drug Use-Related Software (PDURS)
Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) Coverage/reimbursement DTx products FDA Prescription Drug Use-Related Software (PDURS)
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2025 · second_quarter · Q2
Engage Senate and House on proposed legislation to promote the appropriate use of FDA cleared preeclampsia biomarker testing as part of the Medicaid program
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2025 · second_quarter · Q2
Advocacy for FY26 HHS Funding
Filing targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2025 · second_quarter · Q2
FY26 Appropriations advocacy on behalf of NCATS
FY26 Appropriations advocacy on behalf of NCATS
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY via BLUEBIRD STRATEGIES
2025 · second_quarter · Q2
Funding eligibility for FSHD research as part of the FY26 Senate Defense Peer Reviewed Medical Research Program
Filing targets: SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2025 · second_quarter · Q2
Funding for myotonic dystrophy research as part of the FY26 Congressionally Directed Medical Research Program
Myotonic dystrophy biomedical research funding
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2025 · second_quarter · Q2
NIH INCLUDE Down syndrome research funding
DeOndra Dixon INCLUDE Project Act (H.R. 3491/S. 1838)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
CELLTRION USA, INC. via BLUEBIRD STRATEGIES
2025 · second_quarter · Q2
Issues related to drug pricing, FDA drug regulations
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY via BLUEBIRD STRATEGIES
2025 · first_quarter · Q1
Funding eligibility for FSHD research as part of the FY26 Senate Defense Peer Reviewed Medical Research Program
Filing targets: SENATE
FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) SOCIETY via BLUEBIRD STRATEGIES
2025 · first_quarter · RR
FSHD eligibility under the FY26 Senate Defense Peer Reviewed Medical Research Program (PRMRP)
DIGITAL THERAPEUTICS ALLIANCE via BLUEBIRD STRATEGIES
2025 · first_quarter · 1T
Medicare/Medicaid coverage for prescription digital therapeutics
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2025 · first_quarter · Q1
FY26 Appropriations advocacy on behalf of NCATS
FY26 Appropriations advocacy on behalf of NCATS
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2025 · first_quarter · Q1
Advocacy for FY26 HHS Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2025 · first_quarter · Q1
NIH INCLUDE Down syndrome research funding
Reintroduction of DeOndra Dixon INCLUDE Project Act (no bill number in Q1)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2025 · first_quarter · Q1
Funding for myotonic dystrophy research as part of the FY26 Congressionally Directed Medical Research Program
Myotonic dystrophy biomedical research funding
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2025 · first_quarter · Q1
Engage Senate and House on proposed legislation to promote the appropriate use of FDA cleared preeclampsia biomarker testing as part of the Medicaid program
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2024 · fourth_quarter · Q4
FY2025 NCATS research funding
FY2025 NCATS funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2024 · fourth_quarter · Q4
Peggy Lillis C. difficile Inclusion Act (H.R. 9098) CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DIGITAL THERAPEUTICS ALLIANCE via BLUEBIRD STRATEGIES
2024 · fourth_quarter · Q4
Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458/S. 723) American Medical Innovation and Investment Act (H.R. 8816)
CELLTRION USA, INC. via BLUEBIRD STRATEGIES
2024 · fourth_quarter · Q4
Regulation of biosimilar products
FDA regulatory matters
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2024 · fourth_quarter · Q4
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS SEP-1 measure implementation. CDC AMR activities. Issues related to health insurance coverage and regulation of FDA cleared biomarkers to predict preeclampsia.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2024 · fourth_quarter · Q4
Federal funding for NIH research.
DeOndra Dixon INCLUDE Project Act (HR 7406/S.3981)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2024 · fourth_quarter · Q4
Federal funding for NIH research.
Increasing funding for Myotonic Dystrophy research. Fiscal Year 2025 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2024 · first_quarter · 1A
FY2025 NCATS research funding
FY2025 NCATS funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2024 · third_quarter · Q3
Peggy Lillis C. difficile Inclusion Act (H.R. 9098) CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via BLUEBIRD STRATEGIES
2024 · third_quarter · 3T
Legislation to regulate clinical testing/labs.
Medicaid coverage for mental health genetic testing. VA access for mental health genetic testing.
Medicaid precision medicine legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2024 · third_quarter · Q3
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS SEP-1 measure implementation. CDC AMR activities. Issues related to health insurance coverage and regulation of FDA cleared biomarkers to predict preeclampsia.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2024 · third_quarter · Q3
FY2025 NCATS funding
FY2025 NCATS research funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2024 · third_quarter · Q3
Federal funding for NIH research.
DeOndra Dixon INCLUDE Project Act (HR 7406/S.3981)
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2024 · third_quarter · Q3
Federal funding for NIH research.
Increasing funding for Myotonic Dystrophy research. Fiscal Year 2025 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
DIGITAL THERAPEUTICS ALLIANCE via BLUEBIRD STRATEGIES
2024 · fourth_quarter · RR
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
CELLTRION USA, INC. via BLUEBIRD STRATEGIES
2024 · fourth_quarter · RR
Issues related to FDA and biosimilars
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2024 · second_quarter · Q2
CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2024 · second_quarter · 2A
FY2025 NCATS research funding
FY2025 NCATS funding
Filing targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2024 · first_quarter · RA
Funding for NCATS; legislation on NIH/NCATS
Funding for NCATS; legislation on NIH/NCATS
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2024 · second_quarter · Q2
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS SEP-1 measure implementation. CDC AMR activities. Issues related to health insurance coverage and regulation of FDA cleared biomarkers to predict preeclampsia.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2024 · second_quarter · Q2
Federal funding for NIH research.
Increasing funding for Myotonic Dystrophy research. Fiscal Year 2025 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2024 · second_quarter · Q2
Federal funding for NIH research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
MYRIAD GENETICS, INC. via BLUEBIRD STRATEGIES
2024 · second_quarter · Q2
Medicaid coverage for mental health genetic testing. VA access for mental health genetic testing.
Legislation to regulate clinical testing/labs.
Medicaid precision medicine legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NCATS ALLIANCE via BLUEBIRD STRATEGIES
2024 · first_quarter · RR
NIH/NCATS Approproations & Related Policy/Legislative Matters
NIH/NCATS Approproations & Related Policy/Legislative Matters
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2024 · first_quarter · Q1
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics. Issues related to health insurance coverage and regulation of FDA cleared biomarkers to predict preeclampsia.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BOEHRINGER INGELHEIM USA CORPORATION via BLUEBIRD STRATEGIES
2024 · first_quarter · 1T
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via BLUEBIRD STRATEGIES
2024 · first_quarter · Q1
Legislation to regulate clinical labs under CLIA and FDA.
Medicaid precision medicine legislation.
Medicaid coverage for mental health genetic testing. VA access for mental health genetic testing.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2024 · first_quarter · Q1
Increasing funding for Myotonic Dystrophy research. Fiscal Year 2024 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.
Federal funding for NIH research.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2024 · first_quarter · Q1
Federal funding for NIH research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2024 · first_quarter · Q1
CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLICK THERAPEUTICS, INC. via BLUEBIRD STRATEGIES
2024 · first_quarter · 1T
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LUMINOPIA, INC. via BLUEBIRD STRATEGIES
2024 · first_quarter · 1T
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2023 · fourth_quarter · Q4
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2023 · fourth_quarter · Q4
CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYRIAD GENETICS, INC. via BLUEBIRD STRATEGIES
2023 · fourth_quarter · Q4
Medicaid coverage for mental health genetic testing. VA access for mental health genetic testing.
Legislation to regulate clinical labs under CLIA and FDA.
Medicaid precision medicine legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MINDMAZE INC. via BLUEBIRD STRATEGIES
2023 · fourth_quarter · 4T
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MYOTONIC via BLUEBIRD STRATEGIES
2023 · fourth_quarter · Q4
Increasing funding for Myotonic Dystrophy research. Fiscal Year 2024 defense appropriations legislation. Peer Review Medical Research Program and Congressional Directed Medical Research Program.
Federal funding for NIH research.
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
GLOBAL DOWN SYNDROME FOUNDATION via BLUEBIRD STRATEGIES
2023 · fourth_quarter · Q4
Federal funding for NIH research.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
LUMINOPIA, INC. via BLUEBIRD STRATEGIES
2023 · fourth_quarter · Q4
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CLICK THERAPEUTICS, INC. via BLUEBIRD STRATEGIES
2023 · fourth_quarter · Q4
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BOEHRINGER INGELHEIM USA CORPORATION via BLUEBIRD STRATEGIES
2023 · fourth_quarter · Q4
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via BLUEBIRD STRATEGIES
2023 · fourth_quarter · 4T
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THERMO FISHER SCIENTIFIC INC via BLUEBIRD STRATEGIES
2023 · third_quarter · Q3
Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act and issues related to sepsis treatment and antibiotic stewardship. CMS coverage for kidney transplant diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
THE PEGGY LILLIS FOUNDATION via BLUEBIRD STRATEGIES
2023 · third_quarter · Q3
CDC Infection Disease Public Health & Epidemiology Funding. Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization. Pioneering Antimicrobial Subscriptions to End Upsurging Resistance PASTEUR Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
OTSUKA AMERICA PHARMACEUTICAL, INC. via BLUEBIRD STRATEGIES
2023 · third_quarter · Q3
H.R. 1458/S. 723, Access to Prescription Digital Therapeutics Act of 2023. Legislation to establish Medicare and Medicaid coverage for prescription digital therapeutics.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE